Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Raised by Invesco Ltd.

Invesco Ltd. increased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 692,464 shares of the company's stock after purchasing an additional 67,285 shares during the quarter. Invesco Ltd. owned 1.43% of Axsome Therapeutics worth $58,589,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of AXSM. Assetmark Inc. purchased a new stake in shares of Axsome Therapeutics in the 4th quarter worth about $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $64,000. KBC Group NV increased its stake in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after purchasing an additional 385 shares in the last quarter. Xponance Inc. raised its position in shares of Axsome Therapeutics by 11.6% during the 4th quarter. Xponance Inc. now owns 2,659 shares of the company's stock worth $225,000 after purchasing an additional 277 shares during the last quarter. Finally, Intrust Bank NA lifted its stake in Axsome Therapeutics by 6.9% in the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company's stock valued at $239,000 after buying an additional 183 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Stock Down 0.0 %

AXSM stock traded down $0.01 during midday trading on Friday, hitting $104.46. 486,786 shares of the company's stock were exchanged, compared to its average volume of 681,291. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of -17.44 and a beta of 0.88. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The firm has a 50 day moving average price of $118.16 and a 200-day moving average price of $102.39. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. On average, analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 22.40% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AXSM. Cantor Fitzgerald restated an "overweight" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. HC Wainwright reiterated a "buy" rating and set a $200.00 price target on shares of Axsome Therapeutics in a report on Thursday, April 3rd. William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Wells Fargo & Company lifted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada raised their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 19th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $169.80.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.